Table 3.
Multivariable logistic analysis for association with DR and DME.#
| Response | Predictors | OR (95% CI) | P |
|---|---|---|---|
| DR | Fasting blood glucose | 1.04 (0.94–1.15) | 0.456 |
| HbA1C | 1.14 (0.95–1.38) | 0.155 | |
| MAU | 1.01 (1.00–1.01) | 0.088 | |
| Duration of diabetes | 1.16 (1.11–1.22) | <0.0001 | |
| Sex, male | 0.79 (0.46–1.32) | 0.361 | |
| PINP | 1.01 (1.00–1.02) | 0.271 | |
| DME | Fasting blood glucose | 1.19 (1.04–1.37) | 0.011 |
| HbA1C | 1.22 (0.92–1.61) | 0.170 | |
| MAU | 1.00 (1.00–1.01) | 0.172 | |
| β-CTx* | 0.36 (0.13–1.02) | 0.053 | |
| Duration of diabetes | 1.23 (1.15–1.32) | <0.0001 | |
| Sex, male | 0.29 (0.12–0.71) | 0.006 | |
| PINP | 1.02 (0.98–1.05) | 0.345 | |
| AZGP1 | 1.00 (1.00–1.00) | 0.223 | |
| FGF21 | 0.99 (0.93–1.04) | 0.607 |
We included variables selected by purposeful selection.
AZGP1, zinc-alpha-2-glycoprotein; β-CTX, beta C-terminal telopeptide of collagen type I; DR, diabetic retinopathy; DME, diabetic macular edema; FGF21, fibroblast growth factor 21; HbA1C, hemoglobin A1C; MAU, microalbuminuria; PINP, procollagen type 1 N-terminal propeptide.
one patient with a high level of AZGP1 was excluded from analysis.
β-CTX was log-transformed in analysis to account for skewness in the data.